Analysts Set Expectations for ChromaDex FY2024 Earnings

ChromaDex Co. (NASDAQ:CDXC) – Stock analysts at HC Wainwright lifted their FY2024 earnings estimates for ChromaDex in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.06 per share for the year, up from their prior estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The business had revenue of $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 5.06%. During the same quarter in the prior year, the business earned ($0.01) earnings per share.

ChromaDex Stock Performance

Shares of CDXC opened at $5.74 on Tuesday. ChromaDex has a 52 week low of $1.32 and a 52 week high of $6.18. The firm has a market capitalization of $435.84 million, a P/E ratio of 574.57 and a beta of 1.88. The company has a 50-day simple moving average of $3.57 and a 200-day simple moving average of $3.24.

Insider Buying and Selling

In related news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Miracle Mile Advisors LLC acquired a new position in ChromaDex in the second quarter worth about $27,000. The Manufacturers Life Insurance Company bought a new stake in ChromaDex during the second quarter worth about $31,000. Merriman Wealth Management LLC bought a new stake in ChromaDex during the second quarter worth about $32,000. Lazard Asset Management LLC bought a new stake in ChromaDex during the first quarter worth about $43,000. Finally, SG Americas Securities LLC bought a new stake in ChromaDex during the first quarter worth about $54,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.